Weiling Medical
Shenzhen company developing a fully implantable brain-computer interface built on a flexible thin-film electrode that lies on the surface of the brain. It raised over RMB 100 million in August 2026 and reported its first human implant, in a patient with locked-in syndrome, in mid-June 2026.
Overview
Weiling Medical Technology (微灵医疗) is a Shenzhen company founded in 2019 by Dr Li Xiaojian, who held academic appointments at the Medical College of Georgia and Northwestern University’s Feinberg School of Medicine for nearly a decade before returning to China. It develops a fully implantable, wirelessly powered brain-computer interface built on a flexible thin-film electrode that lies on the surface of the cortex without penetrating brain tissue. The implant sends signals to an external controller and neurostimulator, which can drive devices such as an exoskeleton.
Funding and clinical status
On 17 August 2026 Weiling closed a round of over RMB 100 million led by Junzhong Capital, with STAR Market-listed Innotek investing through the Jiaxing Innotek Industrial Fund. Earlier investors include Gaorong Capital, Life Park Venture Capital, CDH Investments and Lihe Sci-Tech.
The company reported that a Guangdong hospital implanted its device in mid-June 2026 in a patient with locked-in syndrome after a brainstem haemorrhage, and that after one week of training and four weeks of treatment the patient regained forearm and wrist movement and pinch grip in the left arm. The hospital has not been named and no peer-reviewed report has been cited. The implant is at investigator-initiated trial stage. Separately, a diagnostic electrode array and intracranial EEG system is in Class III registration, which Weiling expects to reach approval within one to two years.
Why it matters
Weiling’s electrode sits on the cortical surface, an approach closer to Precision Neuroscience’s than to the penetrating probes of Neuralink or StairMed. Its near-term commercial test is the diagnostic device registration. The therapeutic implant still needs named-hospital, peer-reviewed clinical results.